Market Cap 852.63M
Revenue (ttm) 54.55M
Net Income (ttm) -193.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -354.85%
Debt to Equity Ratio 0.00
Volume 4,271,800
Avg Vol 1,194,566
Day's Range N/A - N/A
Shares Out 76.88M
Stochastic %K 76%
Beta 2.33
Analysts Strong Sell
Price Target $27.78

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 660 5320
Fax: 415 525 4200
Address:
1700 Owens Street, Suite 205, San Francisco, United States
outlawinvestor1
outlawinvestor1 Oct. 26 at 11:57 AM
$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR
1 · Reply
topstockalerts
topstockalerts Oct. 24 at 2:06 PM
Neuraxis Inc announced it has received FDA clearance for its nerve stimulation technology to treat functional abdominal pain. The U.S. Food and Drug Administration granted 510(k) clearance for Neuraxis’ patented percutaneous electrical nerve field stimulation (PENFS) technology. The treatment is approved for functional abdominal pain associated with functional dyspepsia and related nausea symptoms in patients aged 8 and older. This marks the FDA’s first clearance specifically targeting functional dyspepsia in adults. The decision was supported by clinical literature, including randomized controlled trials and real-world evidence demonstrating the therapy’s safety and efficacy. The FDA initially reviewed data from pediatric patients up to 21 years old, then extrapolated findings to support adult use. The expanded indication allows Neuraxis to target the broader general population with its PENFS technology. $NRIX
0 · Reply
mikailoral
mikailoral Oct. 23 at 6:11 PM
$NRIX What do you think will happen?
3 · Reply
oaksapollo
oaksapollo Oct. 23 at 3:53 PM
$NRIX 80% PR rate in this patient population, damn impressive: x https://haematologica.org/article/view/12804 Also, WM data: https://haematologica.org/article/view/12758
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 23 at 3:43 PM
$NRIX Outstanding article that hits the mark on NRIX's current state. So if you want to refresh your NRIX insights or learn about NRIX from scratch, this is a must read. https://beyondspx.com/quote/NRIX/analysis/nurix-therapeutics-pioneering-protein-degradation-for-a-new-era-of-medicine-nasdaq-nrix
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:17 PM
Wells Fargo has updated their rating for Nurix Therapeutics ( $NRIX ) to Overweight with a price target of 21.
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 9:57 AM
BTIG updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 35 → 27.
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 5:46 PM
Needham updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 27 → 26.
0 · Reply
topstockalerts
topstockalerts Oct. 22 at 4:13 PM
Shares of Nurix Therapeutics Inc. rose on Wednesday after the company announced the launch of its pivotal DAYBreak clinical trial — a single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The clinical-stage biopharmaceutical company, focused on targeted protein degradation therapies, will evaluate a 600 mg once-daily dose in the DAYBreak study. This dosage was selected following analysis from a randomized cohort in the Phase 1b trial, in alignment with global regulators including the FDA, the UK’s MHRA, and the EMA. “The initiation of the DAYBreak study marks Nurix’s transition to a pivotal-stage company and represents an important milestone for bexobrutideg, which our data suggest has a potentially best-in-class profile,” said Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix. The DAYBreak trial will enroll CLL patients whose disease has progressed after multiple prior treatments. $NRIX
0 · Reply
oaksapollo
oaksapollo Oct. 22 at 1:25 PM
$NRIX only one thing surprised me in the deck and it’s how bad KT-474 data looks. It’s almost as if they’re intentionally not fully degrading the target. Any $KYMR investors understand this? It appears that the DMSO control for KT-474 had less IRAK4 expression to start with, but you can still see a band at every concentration of KT-474.
1 · Reply
Latest News on NRIX
Nurix: An Attractive Early-Stage Biotech Play

Oct 8, 2024, 10:58 AM EDT - 1 year ago

Nurix: An Attractive Early-Stage Biotech Play


outlawinvestor1
outlawinvestor1 Oct. 26 at 11:57 AM
$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR
1 · Reply
topstockalerts
topstockalerts Oct. 24 at 2:06 PM
Neuraxis Inc announced it has received FDA clearance for its nerve stimulation technology to treat functional abdominal pain. The U.S. Food and Drug Administration granted 510(k) clearance for Neuraxis’ patented percutaneous electrical nerve field stimulation (PENFS) technology. The treatment is approved for functional abdominal pain associated with functional dyspepsia and related nausea symptoms in patients aged 8 and older. This marks the FDA’s first clearance specifically targeting functional dyspepsia in adults. The decision was supported by clinical literature, including randomized controlled trials and real-world evidence demonstrating the therapy’s safety and efficacy. The FDA initially reviewed data from pediatric patients up to 21 years old, then extrapolated findings to support adult use. The expanded indication allows Neuraxis to target the broader general population with its PENFS technology. $NRIX
0 · Reply
mikailoral
mikailoral Oct. 23 at 6:11 PM
$NRIX What do you think will happen?
3 · Reply
oaksapollo
oaksapollo Oct. 23 at 3:53 PM
$NRIX 80% PR rate in this patient population, damn impressive: x https://haematologica.org/article/view/12804 Also, WM data: https://haematologica.org/article/view/12758
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 23 at 3:43 PM
$NRIX Outstanding article that hits the mark on NRIX's current state. So if you want to refresh your NRIX insights or learn about NRIX from scratch, this is a must read. https://beyondspx.com/quote/NRIX/analysis/nurix-therapeutics-pioneering-protein-degradation-for-a-new-era-of-medicine-nasdaq-nrix
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:17 PM
Wells Fargo has updated their rating for Nurix Therapeutics ( $NRIX ) to Overweight with a price target of 21.
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 9:57 AM
BTIG updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 35 → 27.
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 5:46 PM
Needham updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 27 → 26.
0 · Reply
topstockalerts
topstockalerts Oct. 22 at 4:13 PM
Shares of Nurix Therapeutics Inc. rose on Wednesday after the company announced the launch of its pivotal DAYBreak clinical trial — a single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The clinical-stage biopharmaceutical company, focused on targeted protein degradation therapies, will evaluate a 600 mg once-daily dose in the DAYBreak study. This dosage was selected following analysis from a randomized cohort in the Phase 1b trial, in alignment with global regulators including the FDA, the UK’s MHRA, and the EMA. “The initiation of the DAYBreak study marks Nurix’s transition to a pivotal-stage company and represents an important milestone for bexobrutideg, which our data suggest has a potentially best-in-class profile,” said Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix. The DAYBreak trial will enroll CLL patients whose disease has progressed after multiple prior treatments. $NRIX
0 · Reply
oaksapollo
oaksapollo Oct. 22 at 1:25 PM
$NRIX only one thing surprised me in the deck and it’s how bad KT-474 data looks. It’s almost as if they’re intentionally not fully degrading the target. Any $KYMR investors understand this? It appears that the DMSO control for KT-474 had less IRAK4 expression to start with, but you can still see a band at every concentration of KT-474.
1 · Reply
LongTrainRunning
LongTrainRunning Oct. 22 at 1:16 PM
$NRIX interesting timing for a secondary. We're close to our 52 week lows and they choose now dilute by a third? We're not cash strapped so why not wait until after NX-5948 data comes out at ASH in December when we'll presumably be higher? I'll never understand the timing of these moves.
1 · Reply
OpenOutcrier
OpenOutcrier Oct. 22 at 12:51 PM
$NRIX (+14.3% pre) Nurix begins pivotal study of bexobrutideg for blood cancer https://ooc.bz/l/81388
0 · Reply
LabPsycho
LabPsycho Oct. 22 at 12:48 PM
$NRIX @outlawinvestor1 If you posted and updated comparison table, $PRLD would move close to the top as 1 month gainers.
1 · Reply
rag2riches
rag2riches Oct. 22 at 12:10 PM
$NRIX DAYbreak trials will be worth multiple billions. Will easily recruit and AA is almost a given. Next pharmacyclics asset here. Astrazeneca has to be intersted in this
0 · Reply
Stmkr
Stmkr Oct. 22 at 11:28 AM
$NRIX Nice offering
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:51 PM
Mizuho has updated their rating for Nurix Therapeutics ( $NRIX ) to Outperform with a price target of 24.
0 · Reply
oaksapollo
oaksapollo Oct. 20 at 11:06 PM
$NRIX Lots to think about here: https://www.nurixtx.com/wp-content/uploads/2025/10/NX-1607-ESMO-2025-Poster-Final.pdf
3 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 11:51 AM
HC Wainwright & Co. updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 33.
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 10:13 AM
Needham updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 27.
0 · Reply
LongTrainRunning
LongTrainRunning Oct. 18 at 10:24 AM
$NRIX NX-1607 update from ESMO: NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in tumor biomarkers, tumor shrinkage, long-term stable disease, and a confirmed partial response in heavily pretreated patients Data support initiation of expansion cohorts at the two highest doses tested as monotherapy or combination for the treatment of advanced solid tumors. https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-new-clinical-data-first-class-oral/
2 · Reply
LongTrainRunning
LongTrainRunning Oct. 17 at 4:06 PM
ESMO (European Society for Medical Oncology) is this weekend. On Sep. 10, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference, $NRIX CEO Dr. Sands said, "We did recently disclose that we will have a publication at ESMO for 1607, which is focused on our Phase I results." I cannot find any record of that recent disclosure or of the publication. The last day of ESMO is Monday. So I wonder if he misspoke or if there will in fact be a 1607 update this weekend? Don't let us down Arthur!
1 · Reply
oaksapollo
oaksapollo Oct. 16 at 5:21 PM
$NRIX dang Dec $16, calls trading at $0.50-0.55 with decent volume. Strong bids for $14, $15, and $16 strikes. Very bullish.
0 · Reply